Qiagen N.v. · NYSE:QGEN
Qiagen — Investor Day (November 2016)
14 slides from Qiagen's investor day presentation, Nov 15, 2016
Slide 1: Life Sciences: Innovator at the leading edge of research
Life Sciences: Innovator at the leading edge of research Brad Crutchfield Senior Vice President, Head of Life Sciences Business Areas November 15, 2016 Sample to Insight 2016 Analyst & Investor Day 1
Slide 2: Disclaimer
Disclaimer Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended
Slide 3: Sample to Insight
Sample to Insight 2016 Analyst & Investor Day 3
Slide 4: Recognized innovator supporting breakthroughs in Life Sciences
Copenhagen, Life Sciences Denmark Brad Crutchfield Senior Vice President, Business Area Life Sciences Joined QIAGEN in 2015 2015 total sales: ~$644 million Redwood City, California Life Sciences employees: ~400 San Diego, California Frederick, Hilden, Beijing, Maryland Germany China Addressable mark
Slide 5: Insights valued over the process
Offers technology support in Build their own workflows by pulling response to customer request components from various vendors and seek technology support Supplier Customer Components catalogue Challenges Sample technology kits Complexity and cost Assay systems Biology vs. technology Instr
Slide 6: Our ambition: QIAGEN, the leader at creating solutions that drive insights
QIAGEN supports customers with Customers create their own ecosystem Sample to Insight solutions to drive discovery process Sample Assay Technologies Technologies Automation systems Bioinformatics Customer BIOLOGICAL SAMPLE TO INSIGHT VALUABLE SAMPLE MOLECULAR INSIGHTS Our ambition: QIAGEN, the leade
Slide 7: Strategy: Offer Sample to Insight workflows at leading edges of discovery
Foundation for growth Leverage emerging applications Win at the bench Relevant workflows create differentiation Inspire discovery Empowered to ask increasingly complex questions Strategy: Offer Sample to Insight workflows at leading edges of discovery Sample to Insight 2016 Analyst & Investor Day 7
Slide 8: Capturing opportunities by creating differentiated Sample to Insight workflows
Single-cell Liquid biopsy Microbiome Human ID / Forensics research ~$200 ~$100 ~$150 ~$350 million million million million opportunity opportunity opportunity opportunity Cells Sample Technologies Cells Cells Cells Blood Blood Environmental Tissue Environmental PCR PCR PCR PCR NGS NGS NGS NGS Assay
Slide 9: Case study: Digital NGS enabled by QIAGEN's proprietary molecular index technology
Case study: Digital NGS enabled by QIAGEN’s proprietary molecular index technology Molecular Tagging gene transcripts prior to amplification barcoding Identifying and counting unique transcripts Single primer No restrictions of two-target primer design extension Uniform PCR reactions without
Slide 10: Case study: Liquid biopsy
Case study: Liquid biopsy Technology focus areas Circulating Exosomes Free circulating tumor cells nucleic acids ~$200 million (DNA) (DNA / RNA) (DNA / RNA) opportunity Most comprehensive liquid biopsy portfolio Concept first published in a 1947 scientific article Non-invasive alternative to a t
Slide 11: Case study: Microbiome
Case study: Microbiome Technology focus areas Extraction from complex No bias in NGS Turning micro- metagenomic samples library preparation biome data into insights Inhibitor removal from samples ~$100 million opportunity QIAGEN microbiome workflows Microbiomes first recognized in the 1990s Chal
Slide 12: QIAscout – Single-cell isolation for every lab
Case study: Single-cell research Technology focus areas 20% Immunology 40% Cancer 10% Neuroscience 10% Stem cell ~$150 million opportunity 20% Other QIAscout – Single-cell isolation for every lab Focus on unique cell populations over time Analyzing heterogeneous cellular activity PCR QIAscout RE
Slide 13: 2017-2020 R&D themes: New solutions to better transform samples into insights
Single-cell research: Microbiome: Practical solutions Creating the standards Bioinformatics: Liquid biopsy: Further integration into workflows Sample to Lowering limits of detection Insight user experience Sample technologies: Automation solutions: Faster, easier, better Improving lab workflows In-s
Slide 14: A trusted innovator in Life Science Research
A trusted innovator in Life Science Research Unique position to deliver solutions Differentiation with the best user experience Transforming samples into valuable insights Sample to Insight 2016 Analyst & Investor Day 14